predomin
etiolog
agent
common
cold
human
rhinoviru
hrv
lead
caus
human
infecti
diseas
earli
studi
show
monoval
inactiv
hrv
vaccin
protect
virusneutr
antibodi
nab
correl
protect
howev
cocircul
mani
hrv
type
discourag
vaccin
effort
approach
problem
straightforwardli
test
hypothesi
increas
viru
input
titer
polyval
inactiv
hrv
vaccin
result
broad
nab
respons
show
serum
nab
mani
rhinoviru
type
induc
polyval
inactiv
hrv
plu
alhydrogel
alum
adjuv
use
formul
mice
rhesu
macaqu
hrv
vaccin
immunogen
relat
suffici
quantiti
input
antigen
valenc
major
factor
potenc
breadth
respons
first
time
gener
vaccin
capabl
induc
nab
respons
numer
divers
hrv
type
hrv
caus
respiratori
ill
billion
peopl
annual
socioeconom
burden
hrv
also
caus
pneumonia
hospit
children
adult
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
hrv
found
second
lead
caus
communityacquir
pneumonia
requir
hospit
us
children
second
respiratori
syncyti
viru
common
pathogen
associ
pneumonia
hospit
us
adult
vaccin
hrv
could
allevi
seriou
diseas
asthma
virusneutr
antibodi
nab
correl
protect
estim
durat
immun
trial
monoval
hrv
vaccin
demonstr
protect
homolog
challeng
diseas
achiev
formalininactiv
viru
given
intramuscularli
im
intranas
humor
immun
heterolog
viru
type
observ
though
crossreact
cell
promot
clearanc
limit
cross
neutral
ab
induc
hyperimmun
anim
possibl
vaccin
compos
distinct
hrv
antigen
view
formid
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
nab
guinea
pig
reciproc
serum
nab
titer
result
four
dose
dilut
vaccin
correl
vaccin
efficaci
human
although
nab
titer
requir
protect
defin
earli
studi
establish
inactiv
hrv
protect
human
immunogen
anim
inform
clinic
test
result
discuss
first
use
balbc
mice
test
immunogen
propag
hrv
cell
inactiv
infect
use
formalin
sera
mice
detect
nab
fig
alum
adjuv
enhanc
nab
respons
induc
im
inactiv
fig
effect
valenc
compar
nab
respons
induc
inactiv
type
vaccin
fig
tissu
cultur
infecti
dose
tcid
titer
input
virus
prior
inactiv
inactivatedtcid
provid
supplement
tabl
origin
antigen
sin
occur
sequenti
exposur
relat
viru
variant
result
bias
immun
type
encount
first
bival
hrvimmun
mice
observ
modest
origin
antigen
sin
follow
prime
vaccin
inactiv
hrv
boost
vaccin
partial
allevi
effect
supplement
fig
similar
influenza
viru
collect
result
prompt
us
explor
fulli
nab
respons
polyval
hrv
vaccin
report
two
differ
inactiv
hrv
prepar
induc
nab
titer
input
viru
type
recipi
subject
howev
input
titer
virus
prior
inactiv
rang
tcid
per
ml
dilut
gener
ml
dose
given
im
prime
boost
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
adjuv
hypothes
low
input
antigen
dose
respons
poor
nab
respons
inactiv
hrv
reconstitut
vaccin
close
possibl
avail
hrv
type
inactivatedtcid
per
vaccin
dose
compar
vaccin
type
input
titer
rang
inactivatedtcid
per
dose
reconstitut
vaccin
result
detect
nab
prime
vaccin
follow
boost
vaccin
nab
five
type
highest
input
titer
fig
high
titer
vaccin
result
nab
type
prime
vaccin
type
boost
fig
follow
boost
vaccin
appear
inactivatedtcid
per
vaccin
dose
threshold
induct
nab
model
fig
titer
correl
input
load
nab
tabl
accommod
volum
adjust
inactiv
hrv
vaccin
induc
nab
input
type
follow
prime
boost
fig
nab
induc
inactiv
hrv
persist
day
postboost
supplement
fig
inactiv
hrv
prime
vaccin
induc
nab
viru
type
boost
result
nab
type
fig
averag
nab
titer
result
prime
boost
valent
data
demonstr
broad
neutral
divers
hrv
type
straightforward
vaccin
approach
order
increas
vaccin
valenc
chose
rhesu
macaqu
rm
ml
im
tabl
vaccin
induc
nab
rm
rm
b
input
virus
follow
prime
vaccin
fig
vaccin
induc
nab
rm
c
rm
input
virus
follow
prime
vaccin
fig
breadth
nab
follow
prime
vaccin
rm
superior
observ
mice
may
due
anim
speci
differ
andor
higher
inactivatedtcid
input
titer
rm
vaccin
follow
boost
vaccin
serum
nab
titer
type
hrvvaccin
rm
fig
viru
type
vaccin
rm
fig
averag
nab
titer
result
prime
boost
rm
nab
respons
typespecif
cross
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
product
adequ
yield
obtain
cell
supplement
fig
inject
vaccin
requir
defin
puriti
proof
principl
purifi
three
hrv
type
high
perform
liquid
chromatographi
found
uncompromis
immunogen
trival
inactiv
purifi
hrv
mice
supplement
fig
forti
year
ago
prospect
polyval
hrv
vaccin
dour
good
advanc
valenc
may
applic
vaccin
antigen
variabl
pathogen
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
taper
microtip
secur
ring
stand
sonic
perform
oper
close
room
ear
protect
amplitud
sec
sec
interv
puls
per
ml
materi
sonic
yield
higher
titer
freezethaw
suspens
clarifi
centrifug
g
minut
supernat
transfer
cryovial
snap
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
mgkg
telazol
mgkg
anesthesia
fast
anim
follow
anesthesia
ketamin
telazol
anim
bled
femor
vein
yerk
blood
collect
guidelin
follow
day
blood
collect
group
nab
titer
yaxi
measur
indic
type
vaccin
dash
line
repres
lod
undetect
nab
assign
symbol
lod
nudg
visual
three
independ
experi
use
low
input
titer
show
similar
result
statist
signific
associ
input
tcid
viru
titer
detect
nab
respons
follow
prime
p
boost
p
vaccin
fisher
exact
test
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
inactivatedtcid
input
titer
per
dose
specifi
supplement
tabl
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
